HeartBeam Partners with Icahn School of Medicine to Develop AI-ECG Algorithms
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BEAT?
HeartBeam announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The collaboration will leverage HeartBeam's patented ECG platform, which captures the heart's electrical activity from 3 non-coplanar dimensions. The company said, "Under the collaboration, HeartBeam's in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform. Joshua Lampert, MD, FACC, a pioneer in AI-ECG and cardiovascular deep learning research and clinician recognized for his excellence in patient care, Vivek Reddy, MD, an internationally renowned electrophysiologist and innovator, and Girish N. Nadkarni, MD, MPH, the Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will help guide the scientific and clinical development of the partnership."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BEAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BEAT
Wall Street analysts forecast BEAT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.350
Low
4.00
Averages
5.83
High
8.00
Current: 1.350
Low
4.00
Averages
5.83
High
8.00
About BEAT
HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HeartBeam Partners with Mount Sinai for AI Heart Monitoring
- Strategic Collaboration: HeartBeam has announced a strategic partnership with the Icahn School of Medicine at Mount Sinai to accelerate the development of AI-enabled heart monitoring technology, which is expected to drive innovation in cardiac health management.
- Integration of Technical Expertise: This partnership combines Mount Sinai's clinical and AI expertise with HeartBeam's patented 3D electrocardiogram platform, enabling the collection of 12-lead ECG data anytime and anywhere, thus expanding the applications of heart monitoring.
- AI Algorithm Development: By pairing high-fidelity ECG data with clinically annotated datasets, the collaboration aims to create advanced AI algorithms capable of assessing heart health trends earlier, detecting risks, and guiding more precise care.
- Market Potential Enhancement: This collaboration positions HeartBeam to move beyond rhythm monitoring into AI-enabled disease assessment and management, potentially unlocking new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring.
See More
HeartBeam Partners with Mount Sinai for AI-ECG Development
- AI-ECG Collaboration: HeartBeam's partnership with Mount Sinai aims to combine its patented ECG platform with the hospital's AI and clinical expertise to develop and validate advanced AI-ECG algorithms, enhancing the accuracy and efficiency of cardiac health monitoring.
- Data Integration Advantage: The collaboration will leverage HeartBeam's real-world ECG datasets alongside Mount Sinai's clinically annotated data to train and validate new AI models, expected to drive the development of personalized algorithms that enable 12-lead ECG assessments outside traditional clinical settings.
- Accelerated Algorithm Development: HeartBeam's in-house AI team will collaborate with Mount Sinai researchers to develop, train, and validate a suite of AI-ECG algorithms intended to provide patient wellness insights, condition-focused assessments, and chronic condition management, expanding the application scenarios of the cardiac monitoring platform.
- Stock Price Surge: HeartBeam shares rose 6.08% to $1.57 at the time of publication, reflecting positive market sentiment towards the collaboration's prospects, which may enhance investor confidence in the company's future growth potential.
See More
HeartBeam Partners with Mount Sinai to Develop AI-ECG Algorithms
- Strategic Collaboration: HeartBeam has entered a strategic partnership with the Icahn School of Medicine at Mount Sinai to develop and validate next-generation AI-ECG algorithms, leveraging HeartBeam's patented 3D ECG platform to enhance AI-enabled cardiac monitoring as part of the company's broader ecosystem strategy.
- Research Team Formation: Led by Lance Myers, HeartBeam's AI team will collaborate with Mount Sinai researchers to develop and validate advanced AI-ECG algorithms, with guidance from Joshua Lampert, Vivek Reddy, and Girish Nadkarni, ensuring the effectiveness and practicality of the technology.
- Positive Market Reaction: Following the announcement, HeartBeam's shares rose by 5.71%, indicating market recognition of the company's innovative capabilities in cardiac monitoring, which may attract more investor interest in its future growth potential.
- Ecosystem Strategy Enhancement: This collaboration with Mount Sinai not only strengthens HeartBeam's technological capabilities but also solidifies its competitive position in the cardiac health monitoring market, signaling long-term growth potential in the medical technology sector.
See More
HeartBeam to Attend Key Investor Conferences in March 2026
- Investor Conference Schedule: HeartBeam's CEO Robert Eno and CFO Timothy Cruickshank will attend the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026, where they will host a webcast presentation and one-on-one meetings with investors to enhance the company's visibility among stakeholders.
- Industry Engagement Opportunity: At the ROTH Conference on March 23-24, 2026, CEO Eno will participate in a panel discussion on ‘Technologies Advancing Healthy Aging,’ showcasing HeartBeam's innovations in cardiac health management and further solidifying its leadership position in the industry.
- Scientific Conference Participation: The HeartBeam team will attend the American College of Cardiology's annual conference (ACC.26) from March 28-30, 2026, showcasing their FDA-cleared HeartBeam System at booth #209 and demonstrating the working prototype of the 12-lead ECG extended wear patch to physicians and potential partners, thereby enhancing market awareness.
- Technology Innovation Showcase: HeartBeam's 3D ECG technology received FDA clearance in 2024, aimed at providing real-time cardiac health monitoring through portable devices, which is expected to redefine the future of cardiac health management and improve patient health management experiences.
See More
Beatbot Launches AquaSense X Ecosystem at $4,250, CES 2026 Honoree
- Intelligent Cleaning System: The Beatbot AquaSense X robot, powered by AI 2.0 and HybridSense™ technology, doubles the debris types recognized from 20 to 40 and expands cleaning coverage from the pool floor to the water surface, significantly enhancing cleaning efficiency and user experience.
- Maintenance Innovation: The AstroRinse cleaning station introduces the world's first fully automatic filter-cleaning system, completing filter cleaning in just three minutes without manual maintenance, greatly simplifying post-cleaning tasks and improving user satisfaction.
- Market Recognition: The AquaSense X system has been honored with a CES 2026 Innovation Award in the Home Appliances category, highlighting Beatbot's successful integration of high-end robotic engineering with user-friendly design, further solidifying its market leadership.
- Product Launch and Preorder: The AquaSense X ecosystem will be available on January 5, 2026, priced at $4,250, with the first 500 customers able to join a limited preorder program with a $250 deposit, generating significant interest among potential users.
See More
Aditxt Shares Surge Approximately 63%; Check Out 20 Stocks Making Moves in Premarket Trading
Aditxt Inc Stock Surge: Aditxt Inc's shares rose 63.4% to $2.32 in pre-market trading after filing a definitive proxy statement for a special stockholder meeting on January 30, 2026, regarding compliance with Nasdaq rules on share issuances.
Other Notable Gainers: Several stocks saw significant pre-market gains, including Agape ATP Corp (+66%), Direct Digital Holdings Inc (+35.3%), and DBV Technologies SA (+30.3%) following positive trial results.
Major Losers: Children's Place Inc experienced a sharp decline of 32.1% to $4.99 after disappointing third-quarter results, while other notable losers included AlphaVest Acquisition Corp (-19.8%) and Kyverna Therapeutics Inc (-19.2%).
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies recovering from previous declines while others faced significant drops in share prices.
See More
HeartBeam Partners with Mount Sinai for AI Heart Monitoring
- Strategic Collaboration: HeartBeam has announced a strategic partnership with the Icahn School of Medicine at Mount Sinai to accelerate the development of AI-enabled heart monitoring technology, which is expected to drive innovation in cardiac health management.
- Integration of Technical Expertise: This partnership combines Mount Sinai's clinical and AI expertise with HeartBeam's patented 3D electrocardiogram platform, enabling the collection of 12-lead ECG data anytime and anywhere, thus expanding the applications of heart monitoring.
- AI Algorithm Development: By pairing high-fidelity ECG data with clinically annotated datasets, the collaboration aims to create advanced AI algorithms capable of assessing heart health trends earlier, detecting risks, and guiding more precise care.
- Market Potential Enhancement: This collaboration positions HeartBeam to move beyond rhythm monitoring into AI-enabled disease assessment and management, potentially unlocking new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring.
See More
HeartBeam Partners with Mount Sinai for AI-ECG Development
- AI-ECG Collaboration: HeartBeam's partnership with Mount Sinai aims to combine its patented ECG platform with the hospital's AI and clinical expertise to develop and validate advanced AI-ECG algorithms, enhancing the accuracy and efficiency of cardiac health monitoring.
- Data Integration Advantage: The collaboration will leverage HeartBeam's real-world ECG datasets alongside Mount Sinai's clinically annotated data to train and validate new AI models, expected to drive the development of personalized algorithms that enable 12-lead ECG assessments outside traditional clinical settings.
- Accelerated Algorithm Development: HeartBeam's in-house AI team will collaborate with Mount Sinai researchers to develop, train, and validate a suite of AI-ECG algorithms intended to provide patient wellness insights, condition-focused assessments, and chronic condition management, expanding the application scenarios of the cardiac monitoring platform.
- Stock Price Surge: HeartBeam shares rose 6.08% to $1.57 at the time of publication, reflecting positive market sentiment towards the collaboration's prospects, which may enhance investor confidence in the company's future growth potential.
See More
HeartBeam Partners with Mount Sinai to Develop AI-ECG Algorithms
- Strategic Collaboration: HeartBeam has entered a strategic partnership with the Icahn School of Medicine at Mount Sinai to develop and validate next-generation AI-ECG algorithms, leveraging HeartBeam's patented 3D ECG platform to enhance AI-enabled cardiac monitoring as part of the company's broader ecosystem strategy.
- Research Team Formation: Led by Lance Myers, HeartBeam's AI team will collaborate with Mount Sinai researchers to develop and validate advanced AI-ECG algorithms, with guidance from Joshua Lampert, Vivek Reddy, and Girish Nadkarni, ensuring the effectiveness and practicality of the technology.
- Positive Market Reaction: Following the announcement, HeartBeam's shares rose by 5.71%, indicating market recognition of the company's innovative capabilities in cardiac monitoring, which may attract more investor interest in its future growth potential.
- Ecosystem Strategy Enhancement: This collaboration with Mount Sinai not only strengthens HeartBeam's technological capabilities but also solidifies its competitive position in the cardiac health monitoring market, signaling long-term growth potential in the medical technology sector.
See More
HeartBeam to Attend Key Investor Conferences in March 2026
- Investor Conference Schedule: HeartBeam's CEO Robert Eno and CFO Timothy Cruickshank will attend the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026, where they will host a webcast presentation and one-on-one meetings with investors to enhance the company's visibility among stakeholders.
- Industry Engagement Opportunity: At the ROTH Conference on March 23-24, 2026, CEO Eno will participate in a panel discussion on ‘Technologies Advancing Healthy Aging,’ showcasing HeartBeam's innovations in cardiac health management and further solidifying its leadership position in the industry.
- Scientific Conference Participation: The HeartBeam team will attend the American College of Cardiology's annual conference (ACC.26) from March 28-30, 2026, showcasing their FDA-cleared HeartBeam System at booth #209 and demonstrating the working prototype of the 12-lead ECG extended wear patch to physicians and potential partners, thereby enhancing market awareness.
- Technology Innovation Showcase: HeartBeam's 3D ECG technology received FDA clearance in 2024, aimed at providing real-time cardiac health monitoring through portable devices, which is expected to redefine the future of cardiac health management and improve patient health management experiences.
See More
Beatbot Launches AquaSense X Ecosystem at $4,250, CES 2026 Honoree
- Intelligent Cleaning System: The Beatbot AquaSense X robot, powered by AI 2.0 and HybridSense™ technology, doubles the debris types recognized from 20 to 40 and expands cleaning coverage from the pool floor to the water surface, significantly enhancing cleaning efficiency and user experience.
- Maintenance Innovation: The AstroRinse cleaning station introduces the world's first fully automatic filter-cleaning system, completing filter cleaning in just three minutes without manual maintenance, greatly simplifying post-cleaning tasks and improving user satisfaction.
- Market Recognition: The AquaSense X system has been honored with a CES 2026 Innovation Award in the Home Appliances category, highlighting Beatbot's successful integration of high-end robotic engineering with user-friendly design, further solidifying its market leadership.
- Product Launch and Preorder: The AquaSense X ecosystem will be available on January 5, 2026, priced at $4,250, with the first 500 customers able to join a limited preorder program with a $250 deposit, generating significant interest among potential users.
See More
Aditxt Shares Surge Approximately 63%; Check Out 20 Stocks Making Moves in Premarket Trading
Aditxt Inc Stock Surge: Aditxt Inc's shares rose 63.4% to $2.32 in pre-market trading after filing a definitive proxy statement for a special stockholder meeting on January 30, 2026, regarding compliance with Nasdaq rules on share issuances.
Other Notable Gainers: Several stocks saw significant pre-market gains, including Agape ATP Corp (+66%), Direct Digital Holdings Inc (+35.3%), and DBV Technologies SA (+30.3%) following positive trial results.
Major Losers: Children's Place Inc experienced a sharp decline of 32.1% to $4.99 after disappointing third-quarter results, while other notable losers included AlphaVest Acquisition Corp (-19.8%) and Kyverna Therapeutics Inc (-19.2%).
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies recovering from previous declines while others faced significant drops in share prices.
See More
